HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Mycoses (Diseases, Fungus)

Subscribe to New Research on Mycoses

Share|Follow on Twitter

Also Known As:

Diseases, Fungus; Disease, Fungus; Fungus Disease; Fungus Diseases

Networked: 1021 relevant articles (74 outcomes, 140 trials/studies) for this Disease, Comments

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses
- Mycoses: 1021

Related Diseases

1.	Infection
2.	Leukemia
3.	Aspergillosis
4.	Dermatomycoses (Dermatophytosis)
5.	Invasive Candidiasis

Experts

1.	Herbrecht, Raoul: 5 articles (09/2011 - 04/2003)
2.	Lewis, Russell E: 5 articles (08/2011 - 08/2002)
3.	Kontoyiannis, Dimitrios P: 5 articles (05/2010 - 12/2003)
4.	Walsh, Thomas J: 5 articles (07/2009 - 01/2007)
5.	Lass-Flörl, Cornelia: 4 articles (09/2012 - 10/2005)
6.	Cornely, Oliver A: 4 articles (09/2011 - 05/2003)
7.	Marchetti, Oscar: 4 articles (01/2011 - 01/2007)
8.	Singh, Nina: 4 articles (03/2010 - 03/2004)
9.	Perfect, John R: 4 articles (12/2009 - 01/2005)
10.	Calandra, Thierry: 3 articles (01/2011 - 01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mycoses:

1.	Amphotericin B (Amphotericin)FDA LinkGeneric 03/01/2009 - "Amphotericin B (AmB) is the gold standard of antifungal treatment for the most severe invasive mycoses. " 12/01/2000 - "Amphotericin B is the gold standard for antifungal treatment for the most severe mycoses. " 10/01/2003 - "Amphotericin B by various routes is the mainstay of treatment for life-threatening and severe ophthalmic mycoses. " 08/01/1995 - "Amphotericin B (AmB) is widely used for the treatment of systemic mycoses. " 02/01/1985 - "This required choosing of the dose and regimen for the use of amphotericin B, the only drug effective in the treatment of generalized mycoses. " Order ALL the reference details at left...
2.	Itraconazole (Sporanox)FDA LinkGeneric 02/01/1990 - "Oral itraconazole is effective in the treatment of mycoses. " 01/01/1987 - "These results indicate that itraconazole is effective in treating these recalcitrant superficial mycoses and should be assessed in a larger unselected group of patients and compared with alternative drugs." 12/01/2003 - "Oral itraconazole may provide a safe and effective alternative for patients with locally invasive non-disseminated mycoses due to Curvularia species." 11/01/2000 - "The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans." 12/01/1996 - "The efficacy of oral itraconazole 2 x 200 mg capsules daily for prevention of systemic mycoses was investigated in granulocytopenic patients with haematological malignancies. " Order ALL the reference details at left...
3.	Antifungal AgentsIBA 05/01/2000 - "Surgical resection, in combination with antifungal agents, is a safe and effective form of therapy for invasive mycoses. " 06/01/2006 - "The availability of new antifungal agents with novel mechanisms of action and improved tolerability has widened the possibilities for combination therapy for difficult-to-treat opportunistic mycoses. " 07/01/2004 - "The availability of new antifungal agents with unique mechanisms of action and improved tolerability has widened the possibilities for the use of combination antifungal therapy for difficult-to-treat opportunistic mycoses. " 01/01/2003 - "Development of new antifungal agents and combination therapies may result in improvement in the management of subcutaneous mycoses in the future." 08/01/2006 - "Antifungal combinations are increasingly used in clinical practice to improve outcomes for refractory mycoses because of the suboptimal efficacy of current antifungal agents. " Order ALL the reference details at left...
4.	Fluconazole (Zonal)FDA LinkGeneric 11/01/1995 - "A clinical study was conducted to test the efficacy of fluconazole in the treatment of tropical deep mycoses. " 03/01/1992 - "Eighty-eight immunocompetent patients with deep mycoses from eight countries were evaluated with the same protocol for efficacy of fluconazole monotherapy. " 05/23/2000 - "To study the therapy, efficacy and safety of fluconazole in candidal mycoses during neonatal phase and infancy a case review in 53 newborns and infants was performed. " 09/01/1997 - "The possible adverse effects of chronic, high-dose fluconazole therapy are detailed from analysis of a multicenter, dose-escalating study of the therapy of invasive mycoses. " 04/01/1997 - "The purpose of this prospective, open-label, noncomparative, multicentre study was to evaluate the efficacy and safety of fluconazole in the treatment of hospitalised patients with mycoses. " Order ALL the reference details at left...
5.	terbinafine (Lamisil)FDA LinkGeneric 05/01/2010 - "To evaluate the in vitro efficacy of terbinafine activity against filamentous fungi and yeasts that cause mycoses. " 05/01/2010 - "Evaluation of the disk-diffusion method to determine the in vitro efficacy of terbinafine against subcutaneous and superficial mycoses agents." 12/01/2011 - "Our results provide evidence supporting the use of terbinafine as an oral therapeutic agent for treating systemic and subcutaneous mycoses in dogs." 02/01/2008 - "We review the current literature with regard to in vitro data and clinical experience with terbinafine in the treatment of rare and refractory mycoses." 02/01/2008 - "Use of terbinafine in rare and refractory mycoses." Order ALL the reference details at left...
6.	Ketoconazole (Nizoral)FDA LinkGeneric 07/01/1982 - "Ketoconazole is effective in suppressing disease in various mycoses. " 05/01/1986 - "Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels." 03/01/2004 - "For almost a decade, ketoconazole was regarded as the drug of choice in nonlife-threatening endemic mycoses. " 01/01/1998 - "All patients received ketoconazole (400 mg/day) for various mycoses. " 01/01/1989 - "Ketoconazole administered orally is used in the treatment of superficial and deep mycoses. " Order ALL the reference details at left...
7.	liposomal amphotericin B FDA Link 12/01/1998 - "However, despite administration of liposomal amphotericin-B culture-proven mycoses were associated with a high morbidity (93,3%). " 01/01/1996 - "Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience." 06/01/1994 - "Treatment of deep mycoses with liposomal amphotericin B." 05/01/1992 - "Ambisome could represent an important advance in antifungal treatment since it allows aggressive treatment and eradication of mycoses refractory to conventional therapy while avoiding renal toxicity." 02/01/1997 - "Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses." Order ALL the reference details at left...
8.	micafungin (FK463)FDA Link 03/31/2009 - "Micafungin is a new and very useful pharmacological tool for the treatment of invasive mycoses with a wide antifungal spectrum for the most common pathogenic fungi. " 06/01/2004 - "Micafungin is quite useful in the treatment of deep mycoses. " 07/18/2002 - "Micafungin is currently in phase III clinical trials worldwide as a parenteral agent for various mycoses, and a new drug application (NDA) was recently filed in Japan." 12/01/2009 - "The filamentous fungus Coleophoma empetri F-11899 produces an echinocandin-like compound FR901379, the original source for micafungin which is prescribed to treat deep-seated mycoses. " 03/31/2009 - "[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]." Order ALL the reference details at left...
9.	sertaconazole FDA Link 05/01/1992 - "Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans." 06/01/2005 - "Various studies carried out in animal models, clinical and toxicologic trials have confirmed the value of sertaconazole in the topical treatment of superficial mycoses in dermatology and gynecology. " 05/01/1992 - "In a randomized, parallel, double-blind trial, the activity of sertaconazole cream was studied in 20 patients suffering from superficial mycoses caused by dermatophytes, confirmed by microscopic examination (KOH) and culture test. " 05/01/1992 - "Study on the sensitizing capacity of the new antimycotic sertaconazole in the treatment of cutaneous mycoses." 01/01/2009 - "Sertaconazole was generally well tolerated in patients with dermatological and gynaecological mycoses. " Order ALL the reference details at left...
10.	Miconazole (Monistat)FDA LinkGeneric 04/01/1985 - "Efficacy of miconazole in superficial mycoses." 10/06/1977 - "Side effects of miconazole for systemic mycoses." 07/01/1977 - "Clinical evaluation of miconazole tincture in skin mycoses." 03/01/1977 - "Treatment of systemic mycoses with miconazole: a review." 08/30/1976 - "Miconazole nitrate (2%) cream was evaluated in the treatment of superficial mycoses. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 11/01/2012 - "We review the current treatments available for superficial mycoses and discuss recent developments in pharmacotherapy and the most useful adjuvant treatments. " 05/01/2011 - "Natural chemosensitizing agents could lower dosages needed for effective chemotherapy of invasive mycoses. " 07/18/2008 - "The potential use of natural, safe chemosensitizing agents in antifungal chemotherapy of human mycoses as an alternative to combination therapy is discussed." 06/01/2006 - "Despite recent additions to our antifungal drug armamentarium, success rates for many mycoses remain unacceptably low and antifungal drug therapy is often limited by toxicity, resistance and high cost. " 12/01/1995 - "It is concluded that these inhalable vapours appear to approach the ideal chemotherapy for respiratory tract mycoses." Order ALL the reference details at left...
2.	Transplants (Transplant) 10/15/2004 - "Epidemiological characteristics of invasive mycoses in organ transplant recipients have evolved sufficiently to warrant thoughtful reconsideration of the subsets of patients and the fungal pathogens to be targeted for antifungal prophylactic trials in the current era. " 05/01/2010 - "Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study." 06/01/2008 - "Moreover, the incidence of invasive mycoses varies in the different post transplant phases. " 02/01/2008 - "The epidemiology of invasive mycoses did not differ significantly between the two types of transplant." 02/01/2006 - "The incidence of invasive mycoses following solid organ transplant ranges from 5 to 42% depending on the organ transplanted. " Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 11/01/2010 - "Challenges and prospects of adoptive immunotherapy in prevention and treatment of opportunistic mycoses in hematologic transplant recipients." 05/01/2010 - "Primary deep cutaneous opportunistic mycoses in OTR occur mainly in the first two yr after transplantation, in renal transplant recipients, and in older patients." 05/01/2010 - "Twenty-two cases of deep cutaneous mycoses were detected, (IR 1.2 cases per 1000 PYs) after a mean follow-up time since transplantation of 2.5 yr +/- 2.0 SD (median 1.8 yr). " 07/01/2008 - "Autopsy findings over a 30-year period (1976 to 2005) from a single institution (Institute of Pathology, University of Essen) were retrospectively classified according to basic disease, frequency of mycoses, kind of mycoses, organs involved, hematopoietic transplantation, and cause of death. " 05/15/2003 - "Systemic mycoses have a high impact on tropical renal-transplant recipients. " Order ALL the reference details at left...
4.	Stem Cell Transplantation 01/01/2006 - "Furthermore, in comparing the rate of mycoses in recipients of stem cell transplantation with that of non-recipients, that of recipients was about 10% higher. " 11/01/2000 - "With the increasing use of aggressive chemotherapy and stem cell transplantation causing profound, prolonged depressed immunity, the risk of invasive mycoses has increased. " 01/01/2011 - "Forty-four allogeneic stem cell transplantation recipients diagnosed with probable or proven IA according to the criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group, were enrolled. " 09/01/2001 - "Opportunistic mycoses have emerged as important causes for morbidity and mortality in pediatric cancer patients, particularly in those with intensively treated hematological malignancies, allogeneic hematopoetic stem cell transplantation, and aplastic anemia. " Order ALL the reference details at left...
5.	Salvage Therapy 10/15/2007 - "Data on bacteremias and invasive mycoses occurring during 3 consecutive protocols for front line (NB-89; NB-92; NB-97) or salvage therapy (TVD) for HR-NB were reviewed. " 09/15/2005 - "Bennett Forum on Deep Mycoses Study Design 2004: Candidiasis and salvage therapy for aspergillosis." Order ALL the reference details at left...

blog comments powered by Disqus

TREATMENT OPTIONS
for Mycoses,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 74 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>